BusinessPROTAGEN Launches NavigAID Assay to Support Clinical Drug Development for Autoimmune DiseasesBy Nasdaq OMXDec 13, 2016, 3:52 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXDec 12, 2016, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXDec 6, 2016, 9:05 PM UTC
BusinessPeregrine to Report Financial Results for Second Quarter of Fiscal Year 2017 After Market Close on December 12, 2016By Nasdaq OMXDec 5, 2016, 9:05 PM UTC
BusinessNew Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals’ PS-Targeting Antibodies in a Preclinical Melanoma ModelBy Nasdaq OMXNov 14, 2016, 1:05 PM UTC
BusinessXOMA Reports Third Quarter 2016 Achievements and Financial ResultsBy Nasdaq OMXNov 9, 2016, 2:00 PM UTC
BusinessNew XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual MeetingBy Nasdaq OMXNov 8, 2016, 2:01 PM UTC
BusinessNew XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual MeetingBy Nasdaq OMXNov 8, 2016, 2:01 PM UTC
